ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2025
Development and evaluation of chitosan-xanthan gum-based controlled release nanoparticles of mebeverine hydrochloride for targeted IBS therapy: in silico, in vitro, and in vivo investigations.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) requires long-term, site-specific therapy. Mebeverine hydrochloride is effective but limited by rapid metabolism and frequent dosing. This study aimed to develop colon-targeted, controlled-release nanoparticles to improve therapeutic efficacy and compliance.
methodsNanoparticles were prepared via chitosan-xanthan gum polyelectrolyte complexation and optimized using a Box-Behnken design. Molecular docking predicted strong binding of mebeverine to the muscarinic acetylcholine receptor (-7.4 kcal/mol). Optimized nanoparticles were enteric-coated with Eudragit S100 for pH-dependent colonic release and evaluated through in vitro dissolution and in vivo efficacy in an acetic acid-induced IBS-D rat model.
resultsOptimized nanoparticles showed a mean size of ~ 380 nm, zeta potential + 25 mV, and entrapment efficiency of 95%. In vitro, the enteric-coated formulation resisted gastric pH and released > 95% drug under colonic conditions within 12 h. In vivo, treated rats demonstrated significantly reduced visceral hypersensitivity (AWR score, p < 0.05), normalized intestinal motility (p < 0.05), and improved behavioral outcomes compared to the IBS group. High-dose nanoparticles performed better than the marketed sustained-release capsule.
conclusionThe chitosan-xanthan gum nanoparticle system enabled sustained, colon-specific delivery of mebeverine hydrochloride with superior therapeutic efficacy in vivo, offering a promising strategy for long-term IBS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.